FDA 522 Zimmer Metal-on-Metal Hip Explant Study

The Food and Drug Administration (FDA), pursuant to Section 522 of the Food, Drug and Cosmetic Act, 21 USC § 3601, has ordered medical device manufacturers, including Zimmer, Inc. (“Zimmer”), to conduct post market surveillance studies of their metal-on-metal hip implants.

Part of the post-market surveillance includes the study of explanted retrievals when made available after medically necessary surgical intervention. Below you will find copies of all the pertinent letters and forms for this activity.

Zimmer Communications

Patient Consent/Decline

Procedures/Protocols

All content herein is protected by copyright, trademarks and other intellectual property rights, as applicable, owned by or licensed to Zimmer Biomet or its affiliates unless otherwise indicated, and must not be redistributed, duplicated or disclosed, in whole or in part, without the express written consent of Zimmer Biomet.  
This material is intended for health care professionals. Distribution to any other recipient is prohibited.
For product information, including indications, contraindications, warnings, precautions, potential adverse effects and patient counseling information, see the package insert and information on this website. To obtain a copy of the current Instructions for Use (IFU) for full prescribing and risk information, please call 1-800-348-2759, press 4 for 411 Technical Support.